Sihuan's First-to-market Generic Drug Roxatidine Receives New Drug Certificate and Approval for Production

Sihuan's First-to-market Generic Drug Roxatidine Receives New Drug Certificate
                         and Approval for Production

Drug set for launch in or before the first quarter of next year; Aims to
target hospital market

To seize huge market opportunities in the digestive system drug market

PR Newswire

HONG KONG, Oct. 31, 2012

HONG KONG, Oct. 31,2012 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group
Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading
pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug
franchise in China's prescription market, is pleased to announce that
Roxatidine Acetate Hydrochloride for Injection ("Roxatidine"), Sihuan
Pharmaceutical's first-to-market generic drug, received a new drug certificate
and approval for production. The Company plans to launch the drug to the
market in or before the first quarter of next year.

Sihuan Pharmaceutical is the first pharmaceutical company to successfully
register and develop Roxatidine in China, and has four years of administrative
protection for the drug. Roxatidine is a fourth generation H[2 ]receptor
antagonist. The drug is categorized into two formulations - oral and
injectable. The oral form of the drug was first launched in Japan in 1986 and
is mainly used for gastric and duodenal ulcers, zollinger-ellison syndrome,
reflux esophagitis and gastritis. The injectable form of the drug, which
debuted in Japan in 1995, is mainly used for gastrointestinal ulcers and
bleeding and pre-anesthesia application. It is one of the few drugs prescribed
in hospitals to treat inpatients suffering from gastrointestinal bleeding.
Currently, Roxatidine is widely used in various countries, including Korea,
Germany, Italy, the Netherlands, Greece and South Africa.

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said,
"Roxatidine has a high clinical value. Based on the hospital retail price, the
market size of the same type of drug has already reached RMB$1 billion.
Leveraging our strong marketing capabilities and nationwide sales and
distribution network, we believe that the official launch and manufacturing of
Roxatidine will not only optimize our product mix, but will also strengthen
our competitiveness and help us develop the market for therapeutic drugs for
the digestive system. Looking forward, we will continue to invest in research
and development in order to strengthen our leading position in the CCV drug
market. Meanwhile, we will seize opportunities in other therapeutic areas to
further boost the continued development of Sihuan, thereby creating lucrative
returns for the Company and its shareholders."

Gastrointestinal ulcers and bleeding is a common disease in China and has a
significant patient base. With the fast-paced living environment, accelerated
urbanization and the persistently high stress levels in China, the incidence
rates of such diseases have been increasing each year. The overall incidences
of digestive diseases afflict 10% - 20% of the total population, and the
recurrence rates are high. As at the end of 2011, the size of the market has
reached RMB$25 billion, bringing promising market potential and prospects.

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading
pharmaceutical company and the largest cardio-cerebral vascular drug franchise
in China's prescription market. The success of the Group can be attributed to
its differentiated and proven sales and marketing model, diversified portfolio
of market leading drugs, extensive nationwide distribution network and strong
research and development capabilities. Its major products such as Kelinao,
Anjieli, Chuanqing, Qu'Ao GM1 and Oudimei are widely used in the treatment of
various cardio-cerebral vascular diseases.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.

Contact: At Hill+Knowlton Strategies Asia, Angela Kung, +852-2894-6374 or
+852-6017-7030, angela.kung@hkstrategies.com; or Crystal Yip, +852-2894-6211
or +852-9720-6445, crystal.yip@hkstrategies.com